Project Grant K99HL177309
Award Date
12/20/24
Completion Date
11/30/26
Dollars Obligated
$124K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Indianapolis, IN 46202, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $165,672 to The Leland Stanford Junior University to investigate the role of cardiac troponin I (cTnI) in mitochondrial dysfunction and its impact on genetic cardiomyopathies. The research aims to 1) determine the effects of cTnI phosphorylation and truncation on mitochondrial function, and 2) evaluate the impact of pathogenic...
This federal Project Grant award, totaling $596,401, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The award, effective May 1, 2025, supports research to investigate the role of a novel long non-coding RNA called MCRL1 in regulating human cardiac and hematopoietic differentiation. The research, conducted by the Trustees of Indiana University (Indiana University Indianapolis), aims to...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $618,045 to the University of Arizona to conduct research on identifying new mechanisms and targets for treating diastolic dysfunction in hypertrophic cardiomyopathy (HCM). The research aims to: 1) fully characterize at the atomic level three specific functional domains of the cardiac thin filament linked to the regulation of...
This Project Grant award of $726,408 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund research to define the role of endothelial TFEB in mitigating cardiovascular toxicity induced by cancer therapies. The award recipient, the University of Cincinnati, will leverage its expertise in endothelial cell biology and transgenic mouse models to explore how modulating the TFEB pathway can protect against...
The federal Project Grant award R01HL179124, totaling $776,791.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The award supports research to study how sequence changes in intrinsically disordered regions of the cardiac troponin protein impact its function and regulation of cardiac muscle contraction. The research team from The Washington University, led by experts in protein disorder, single-molecule...
This $777,258 federal Project Grant, awarded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to improve the understanding of heart failure in patients with hypertrophic cardiomyopathy (HCM). The primary focus is to use advanced cardiac MRI techniques, including exercise cardiac MRI, to better characterize the underlying pathophysiology and guide the use of novel cardiac myosin inhibitor pharmacotherapies or established...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $434,658 to Oakland University to conduct research on the intracellular function of the platelet protein TREM-like transcript-1 (TLT-1). The research aims to characterize the phosphorylation sites of TLT-1 and decipher the intracellular cues that regulate its trafficking in platelets. The...
This federal Project Grant award of $2,010,071 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research on the role of Tie2 signaling in aortic valve remodeling. The award will fund a project to: 1) delineate the unique roles of Tie2 signaling in heart valve remodeling in vivo using genetically modified mouse models; 2) define the role of the Tie2-PI3K/AKT-FOXO1 signaling pathway during semilunar valve...
This federal Project Grant award R01HL174049, in the amount of $777,277.00, was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The funding will support research to elucidate the impact of genetic regulation of regulatory T cell (Treg) CD39 expression on the resolution of cardiac inflammation following myocardial infarction. The project aims to determine how CD39 activity on Tregs impacts cardiac inflammation...
The federal Project Grant award R01HL174473, with total funding of $741,112, was granted by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The funding supports research at The Ohio State University to investigate the impact of the adaptive immune system, specifically CD4+ T-cells, on cardiac electrophysiology and the development of heart failure and cardiac arrhythmias. The key objectives are to delineate the...